The report also lists the products, with their MoA, RoA, and individual shares they might occupy in the market.
A group of inherited retinal diseases – Retinitis pigmentosa – leads to progressive deterioration of the ability of eyes to see. Major symptoms of Retinitis Pigmentosa are loss in the ability to see during the night, the formation of blind spots in the peripheral vision, tunnel vision, and eventually loss of vision.
DelveInsight’s ‘Retinitis Pigmentosa – Pipeline Forecast to 2030‘ report provides a comprehensive understanding of the disease including historical and forecasted Retinitis Pigmentosa epidemiology in the 7MM – Geographies comprising-
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
for the Study Period: 2017-2030.
Retinitis Pigmentosa- Disease Understanding
The epidemiology report gives a thorough understanding of the Retinitis Pigmentosa, including the definition of the disease, etiology, symptoms, pathophysiology, and diagnosis.
The section focuses on present treatment algorithms and guidelines for managing this rare genetic disease.
The diagnosis, prognosis, and management of Retinitis pigmentosa continue to be challenging in current practice, attributed to an incomplete understanding of the pathophysiology of the disease process, complexity due to the involvement of a number of genes, and a lack of evidence-based standardized curative therapies for all forms of Retinitis pigmentosa in major geographies. To-date, the role of various genes and their associated mutations have been implicated in RP, however, the pathophysiology of the disease remains poorly understood.
At present, there are no standard Retinitis pigmentosa treatments available, however, treatments are available for a very rare form of RP and managing some aspects of its clinical manifestations with other new treatments involving gene therapy, transplantation, and implanted electrical devices, being in active development.
Click to know more about Retinitis pigmentosa epidemiological insights.
The guidelines for Retinitis pigmentosa treatment and management varies from geography to geography, and the report sheds light on their variability in the US, Europe, and Japan. The report covers the detailed information of the Retinitis Pigmentosa epidemiology scenario in seven major countries (US, EU5, and Japan).
Request for Sample pages from here.
Retinitis Pigmentosa Pipeline Analysis
“Retinitis Pigmentosa (Retinitis) Pipeline Insight, 2020” report covers a detailed scenario of products in pre-clinical, Phase I, II, III and IV developmental stages. The report provides a detailed picture of the Retinitis Pigmentosa (Retinitis) pipeline landscape is provided, which includes in-depth Retinitis Pigmentosa (Retinitis) commercial assessment and clinical assessment of the Retinitis Pigmentosa (Retinitis) pipeline products from the pre-clinical developmental phase to the marketed phase.
The report elaborately mentions different regulatory guidelines, clinical studies, NDA approvals, and the latest novel and innovative approaches in the Retinitis pigmentosa treatment scenario.
Moreover, the report also covers Retinitis Pigmentosa (Retinitis) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Luxturna is the only standardized approved treatment for a very rare form of RP in the United States & European markets. However, several companies have shifted their focus toward this therapeutic area, and several therapies are expected to enter the market, advancing retinitis pigmentosa pipeline during forecast period, including HORA-RPE65 (Horama), AAV8-RPGR (Nightstar Therapeutics), jCell (jCyte), Renexus (NT-501; Neurotech Pharmaceuticals), and hRPC (ReNeuron Limited).
Retinitis Pigmentosa Pipeline – What our analysts say
Retinitis pigmentosa market size is expected to increase for the study period 2017-30 in the 7MM. The increase would be due to an increase in Retinitis pigmentosa prevalence, increase in R&D, and novel treatment approaches and a robust pipeline.
- A better understanding of disease pathogenesis
- Insights into novel therapeutics for Retinitis Pigmentosa (Retinitis).
- Changing Retinitis Pigmentosa (Retinitis) market landscape, and possible reasons behind
- Factors influencing Retinitis Pigmentosa (Retinitis) R&D.
- A detailed portfolio of Pharma players present in the Retinitis Pigmentosa (Retinitis) treatment market.
- In-depth Retinitis pigmentosa pipeline analysis
Table of Contents
- Key Insights
- Executive Summary of Retinitis Pigmentosa
- Competitive Intelligence Analysis for Retinitis Pigmentosa
- Retinitis Pigmentosa: Market Overview at a Glance
- 5. Retinitis Pigmentosa: Disease Background and Overview
- Patient Journey
- Retinitis Pigmentosa Epidemiology and Patient Population
- 8. Treatment Algorithm, Current Treatment, and Medical Practices
- Unmet Needs
- Key Endpoints of Retinitis Pigmentosa Treatment
- Marketed Products
- 12. Emerging Therapies
- 13. Retinitis Pigmentosa: Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview of Retinitis Pigmentosa
- KOL Views
- Market Drivers
- Market Barriers
- DelveInsight Capabilities
*The table of contents is not exhaustive; will be provided in the final report
Know more about the report from here.
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.
Browse through our vast repository from here.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States